Compare AWI & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AWI | DNTH |
|---|---|---|
| Founded | 1860 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 5.9B |
| IPO Year | 1994 | 2018 |
| Metric | AWI | DNTH |
|---|---|---|
| Price | $168.28 | $77.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 17 |
| Target Price | ★ $207.64 | $140.80 |
| AVG Volume (30 Days) | 270.0K | ★ 865.0K |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | ★ 17.61 | N/A |
| EPS | ★ 3.81 | N/A |
| Revenue | ★ $1,620,800,000.00 | $2,036,000.00 |
| Revenue This Year | $10.24 | N/A |
| Revenue Next Year | $7.19 | N/A |
| P/E Ratio | $44.86 | ★ N/A |
| Revenue Growth | ★ 12.11 | N/A |
| 52 Week Low | $150.28 | $32.28 |
| 52 Week High | $206.08 | $117.88 |
| Indicator | AWI | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 54.29 | 33.18 |
| Support Level | $159.62 | $75.50 |
| Resistance Level | $172.23 | $91.36 |
| Average True Range (ATR) | 3.04 | 4.05 |
| MACD | 0.92 | 0.51 |
| Stochastic Oscillator | 60.70 | 40.47 |
Armstrong World Industries Inc designs and manufactures exterior architectural applications, including ceilings, specialty walls, and exterior metal solutions, using materials such as mineral fiber, fiberglass, metal, felt, architectural resin and glass, wood, wood fiber, and glass-reinforced-gypsum. Its segments include Mineral Fiber, which produces suspended mineral fiber and fiberglass ceiling systems and includes results from the Worthington Armstrong Venture (WAVE) for ceiling suspension system (grid) products; Architectural Specialties, which designs, produces, and sources specialty ceilings, walls, and other architectural applications for commercial settings, with revenues mainly project driven; and Unallocated Corporate. The company operates in the United States and Canada.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.